Eton Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 611.59K shares.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 272.60K shares, a 151.35% increase year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 53.48K shares, a 79.73% decline year-over-year.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 161.93K shares, a 39.20% decline from fiscal 2024.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 266.35K shares, a 28.28% increase from fiscal 2023.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 207.63K shares, a 730.50% increase from fiscal 2022.
- Eton Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 25.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 611.59K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 937.67K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 272.60K shares 10-Q · filed 2026-05-14 | 326.08K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 53.48K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 161.93K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 372.30K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 372.30K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 108.45K shares 10-Q · filed 2026-05-14 | 372.30K shares derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | 263.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 266.35K shares 10-K · filed 2026-03-19 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -197.18K shares derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -192.18K shares derived: sum of 4 quarters · filed 2026-03-19 |
| 2024-03-31 | 2.50K shares 10-Q · filed 2025-05-13 | -192.18K shares derived: sum of 4 quarters · filed 2026-03-19 |
| 2023-12-31 | -199.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 207.63K shares 10-K · filed 2026-03-19 |
| 2023-09-30 | 5.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 407.31K shares derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 427.31K shares derived: sum of 4 quarters · filed 2025-03-18 |
| 2023-03-31 | 402.31K shares 10-Q · filed 2023-05-11 | 427.31K shares derived: sum of 4 quarters · filed 2025-03-18 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | 25.00K shares 10-K · filed 2025-03-18 |
| 2022-09-30 | 25.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | |
| 2019-03-31 | 20.00K shares 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |